ArticleNature2018
Evidence that CD32a does not mark the HIV-1 latent reservoir.
Erratum issuedAbstract read
In one paragraph
Article in Nature, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- FcγRIIIa is a noncanonical costimulatory molecule for CD8 T cells.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Phenotyping Viral Reservoirs to Reveal HIV-1 Hiding Places.Current HIV/AIDS reports · 2025Review
- Eliminating the persistent HIV reservoir based on biomarker expression - How do we get there?Virology · 2025Review
- Effective and targeted latency reversal in CD4Emerging microbes & infections · 2024Article
- Targeted shock-and-kill HIV-1 gene therapy approach combining CRISPR activation, suicide gene tBid and retargeted adenovirus delivery.Gene therapy · 2024Article
- AAV vectors displaying bispecific DARPins enable dual-control targeted gene delivery.Biomaterials · 2023Article
- The hypoxia-regulated ectonucleotidase CD73 is a host determinant of HIV latency.Cell reports · 2023Article
- Antigen specificities of HIV-infected cells: A role in infection and persistence?Journal of virus eradication · 2023Review
- Progress Note 2024: Curing HIV; Not in My Lifetime or Just Around the Corner?Pathogens & immunity · 2023Article
- Review
- Review
- CD32iScience · 2021Article
- The single-cell landscape of immunological responses of CD4+ T cells in HIV versus severe acute respiratory syndrome coronavirus 2.Current opinion in HIV and AIDS · 2021Review
- HIV persistence in subsets of CD4+ T cells: 50 shades of reservoirs.Seminars in immunology · 2021Review
- Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure.Frontiers in immunology · 2021Review
- CD32Frontiers in immunology · 2021Article
- Are Fc Gamma Receptor Polymorphisms Important in HIV-1 Infection Outcomes and Latent Reservoir Size?Frontiers in immunology · 2021Review
- Transcriptional signature of resting-memory CD4 T cells differentiates spontaneous from treatment-induced HIV control.Journal of molecular medicine (Berlin, Germany) · 2020Article
- The Potential of Long-Acting, Tissue-Targeted Synthetic Nanotherapy for Delivery of Antiviral Therapy Against HIV Infection.Viruses · 2020Review
- The landscape of alternative splicing in HIV-1 infected CD4 T-cells.BMC medical genomics · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
14 authors.
Christa E OsunaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
So-Yon LimCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Jessica L KublinCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Richard AppsCenter for Human Immunology, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
Elsa ChenCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Talia M MotaDivision of Infectious Diseases, Weill Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Szu-Han HuangDivision of Infectious Diseases, Weill Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Yanqin RenDivision of Infectious Diseases, Weill Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Nathaniel D BachtelDivision of Infectious Diseases, Weill Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Athe M TsibrisBrigham and Women's Hospital, Boston, Massachusetts Harvard Medical School, Boston, MA, USA.
Margaret E AckermanThayer School of Engineering, Dartmouth College, Hanover, NH, USA.
R Brad JonesDivision of Infectious Diseases, Weill Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Douglas F NixonDivision of Infectious Diseases, Weill Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
James B WhitneyCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. jwhitne2@bidmc.harvard.edu.
Funding
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral EradicationUM1AI126617 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD, NIXON, DOUGLAS F · 2016 to 2020
$28.1MMultidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8MViral dynamics of rebound and control following early treatment of HIV/SIVP01AI131365 · NIAID · BOSTON COLLEGE · PI WHITNEY, JAMES BURTON · 2017 to 2021
$7.5MTLR Immunotherapy to Eradicate Anatomic SIV ReservoirsR01AI127089 · NIAID · BOSTON COLLEGE · PI WHITNEY, JAMES BURTON · 2016 to 2020
$3.5MMechanisms of SIV persistenceR56AI091514 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WHITNEY, JAMES BURTON · 2011 to 2011
$849kTLR Therapy to Eradicate the SIV ReservoirR56AI122942 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WHITNEY, JAMES BURTON · 2016 to 2016
$738kNIAID NIH HHS P01 AI131365NIAID NIH HHS R01 AI127089NIAID NIH HHS R56 AI091514NIAID NIH HHS R56 AI122942NIAID NIH HHS T32 AI007387NIAID NIH HHS UM1 AI126617
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.